Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 184.71
Bid (Size) 180.03 (1)
Ask (Size) 189.93 (1)
Prev. Close 184.71
Today's Range 184.71 - 184.71
52wk Range 141.31 - 248.16
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Summit Therapeutics Rocketed Double-Digits Today
Via The Motley Fool
Topics World Trade
Exposures Tariff
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-2.4%
-2.4%
1 Year
+8.0%
+8.0%

More News

Read More
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
From BeiGene, Ltd.
Via Business Wire
A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts
Via Benzinga
Why Is BeiGene Stock Trading Higher On Wednesday?
Via Benzinga
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio?
Via Benzinga
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
From BeiGene, Ltd.
Via Business Wire
Expert Outlook: BeiGene Through The Eyes Of 4 Analysts
Via Benzinga
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
From BeiGene, Ltd.
Via Business Wire
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
From BeiGene, Ltd.
Via Business Wire
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
From BeiGene, Ltd.
Via Business Wire
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
From BeiGene, Ltd.
Via Business Wire
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the Jefferies London Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
From BeiGene, Ltd.
Via Business Wire
BeiGene Mourns Death of Beloved Board Member Donald Glazer
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
From BeiGene, Ltd.
Via Business Wire
US Listed Chinese Stocks Dominate Another Week - Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Via Benzinga
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
From BeiGene, Ltd.
Via Business Wire

Frequently Asked Questions

Is BeiGene, Ltd. - American Depositary Shares publicly traded?
Yes, BeiGene, Ltd. - American Depositary Shares is publicly traded.
What exchange does BeiGene, Ltd. - American Depositary Shares trade on?
BeiGene, Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BeiGene, Ltd. - American Depositary Shares?
The ticker symbol for BeiGene, Ltd. - American Depositary Shares is BGNE on the Nasdaq Stock Market
What is the current price of BeiGene, Ltd. - American Depositary Shares?
The current price of BeiGene, Ltd. - American Depositary Shares is 184.71
When was BeiGene, Ltd. - American Depositary Shares last traded?
The last trade of BeiGene, Ltd. - American Depositary Shares was at 12/31/24 04:00 PM ET
What is the market capitalization of BeiGene, Ltd. - American Depositary Shares?
The market capitalization of BeiGene, Ltd. - American Depositary Shares is 223.70B
How many shares of BeiGene, Ltd. - American Depositary Shares are outstanding?
BeiGene, Ltd. - American Depositary Shares has 224B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.